<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197935</url>
  </required_header>
  <id_info>
    <org_study_id>WO39392</org_study_id>
    <secondary_id>2016-004734-22</secondary_id>
    <nct_id>NCT03197935</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer</brief_title>
  <acronym>IMpassion031</acronym>
  <official_title>A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global Phase III, double-blind, randomized, placebo-controlled study designed to&#xD;
      evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed&#xD;
      death-ligand 1 [anti-PD-L1] antibody) and nab-paclitaxel followed by doxorubicin and&#xD;
      cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery&#xD;
      with initial clinically assessed triple-negative breast cancer (TNBC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Anticipated">October 21, 2022</completion_date>
  <primary_completion_date type="Actual">April 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population</measure>
    <time_frame>After neoadjuvant study treatment and surgery, up to data cut-off on 03 ApriI 2020</time_frame>
    <description>Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population. pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System</measure>
    <time_frame>After neoadjuvant study treatment and surgery, up to data cut-off on 03 ApriI 2020</time_frame>
    <description>Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in the subpopulation with programmed death-ligand1 (PD-L1)-positive tumor status(tumor-infiltrating immune cell [IC] IC1/2/3) . pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) in All Participants</measure>
    <time_frame>Baseline up to approximately 63 months</time_frame>
    <description>Event-free survival (EFS) defined as the time from randomization until documented disease recurrence, progression, or death from any cause in all participants. EFS events covered under &quot;disease recurrence&quot; will include local, regional, or distant recurrence and contralateral breast cancer. Ipsilateral or contralateral in situ disease and second primary non-breast cancers will not be counted as EFS events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) in Subpopulation With PD-L1-Postive Tumor Status</measure>
    <time_frame>Baseline up to approximately 63 months</time_frame>
    <description>Event-free survival (EFS) defined as the time from randomization until documented disease recurrence, progression, or death from any cause in the subpopulation with PD-L1-positive tumor status. EFS events covered under &quot;disease recurrence&quot; will include local, regional, or distant recurrence and contralateral breast cancer. Ipsilateral or contralateral in situ disease and second primary non-breast cancers will not be counted as EFS events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) in All Participants Who Undergo Surgery</measure>
    <time_frame>Baseline up to approximately 63 months</time_frame>
    <description>Disease-free survival (DFS) defined as the time from surgery until documented disease recurrence or death from any cause in all patients (ITT population) who undergo surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) in Subpopulation of Participants With PD-L1-Positive Tumor Status Who Undergo Surgery</measure>
    <time_frame>Baseline up to approximately 63 months</time_frame>
    <description>Disease-free survival (DFS) defined as the time from surgery until documented disease recurrence or death from any cause in the subpopulation of participants with PD-L1-positive tumor status who undergo surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in All Participants</measure>
    <time_frame>Baseline up to approximately 63 months</time_frame>
    <description>Overall survival (OS) defined as the time from randomization to the date of death from any cause in all participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Subpopulation With PD-L1-Positive Tumor Status</measure>
    <time_frame>Baseline up to approximately 63 months</time_frame>
    <description>Overall survival (OS) defined as the time from randomization to the date of death from any cause in the subpopulation with PD-L1-positive tumor status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Scores for Function (Role/Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30</measure>
    <time_frame>Baseline (Cycle 1 Day 1), on Day 1 of every cycle (C) thereafter (C=28 days from C1 to 5, and 21 days from C6 to 16), at Study Drug Completion/Early Discontinuation, Survival Follow-Up Months 3, 6, 9, 12, 18 and 24 (up to approximately 63 months)</time_frame>
    <description>Mean score in function (role, physical) and global health status(GHS)/ health-related quality of life (HRQoL) by cycle and between treatment arms as assessed by the functional and HRQoL scales of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core30(QLQ C30). The EORTC QLQ-C30 includes five functional scales; a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Scores for Function (Role, Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30</measure>
    <time_frame>Baseline (Cycle 1 Day 1), and on Day 1 of every cycle (C) thereafter (C length=28 days from C1 to 5, and 21 days from C6 to 16), at Study Drug Completion/Early Termination, Survival Follow-Up Months 12, 18, and 24 (up to approximately 63 months)</time_frame>
    <description>Mean change from baseline score in function (role, physical) andglobal health status(GHS)/ health-related quality of life (HRQoL) by cycle and between treatment arms as assessed by the functional and HRQoL scales of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core30(QLQ C30). Note: Cycle=C; Day=D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to approximately 63 months</time_frame>
    <description>Percentage of participants with adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Atezolizumab Concentration (Cmin)</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 2, 3, 4, 6, 8, 12, and 16 (cycle length = 28 days from Cycles 1 to 5, and 21 days from Cycles 6 to 16)</time_frame>
    <description>Minimum observed serum atezolizumab concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Atezolizumab Concentration (Cmax)</measure>
    <time_frame>Day 1 of Cycle 1 post dose (cycle length = 28 days)</time_frame>
    <description>Maximum observed atezolizumab concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab</measure>
    <time_frame>Baseline up to approximately 20 months</time_frame>
    <description>Percentage of participants with anti-drug antibodies (ADAs) to atezolizumab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Atezolizumab and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody</intervention_name>
    <description>Atezolizumab was administered as per schedule described in respective arm.</description>
    <arm_group_label>Atezolizumab and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to atezolizumab was administered as per schedule described in respective arm.</description>
    <arm_group_label>Placebo and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel was administered as per schedule described in the arms.</description>
    <arm_group_label>Atezolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Placebo and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin was administered as per schedule described in the arms.</description>
    <arm_group_label>Atezolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Placebo and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide was administered as per schedule described in the arms.</description>
    <arm_group_label>Atezolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Placebo and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.</description>
    <arm_group_label>Atezolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Placebo and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.</description>
    <arm_group_label>Atezolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Placebo and Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Histologically documented TNBC (negative human epidermal growth factor receptor 2&#xD;
             [HER2], estrogen receptor [ER], and progesterone receptor [PgR] status)&#xD;
&#xD;
          -  Confirmed tumor programmed death-ligand 1 (PD-L1) evaluation as documented through&#xD;
             central testing of a representative tumor tissue specimen&#xD;
&#xD;
          -  Primary breast tumor size of greater than (&gt;) 2 centimeters (cm) by at least one&#xD;
             radiographic or clinical measurement&#xD;
&#xD;
          -  Stage at presentation: cT2-cT4, cN0-cN3, cM0&#xD;
&#xD;
          -  Participant agreement to undergo appropriate surgical management including axillary&#xD;
             lymph node surgery and partial or total mastectomy after completion of neoadjuvant&#xD;
             treatment&#xD;
&#xD;
          -  Baseline left ventricular ejection fraction (LVEF) greater than or equal to (&gt;=) 53&#xD;
             percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)&#xD;
             scans&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in paraffin&#xD;
             blocks (preferred) or at least 20 unstained slides, with an associated pathology&#xD;
             report documenting ER, PgR, and HER2 negativity&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive methods, and agreement to refrain from&#xD;
             donating eggs&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures and agreement to refrain from donating sperm&#xD;
&#xD;
          -  Women who are not postmenopausal or have undergone a sterilization procedure must have&#xD;
             a negative serum pregnancy test result within 14 days prior to initiation of study&#xD;
             drug&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior history of invasive breast cancer&#xD;
&#xD;
          -  Stage 4 (metastatic) breast cancer&#xD;
&#xD;
          -  Prior systemic therapy for treatment and prevention of breast cancer&#xD;
&#xD;
          -  Previous therapy with anthracyclines or taxanes for any malignancy&#xD;
&#xD;
          -  History of ductal carcinoma in situ (DCIS), except for participants treated&#xD;
             exclusively with mastectomy &gt;5 years prior to diagnosis of current breast cancer&#xD;
&#xD;
          -  History of pleomorphic lobular carcinoma in situ (LCIS), except for participants&#xD;
             surgically managed &gt;5 years prior to diagnosis of current breast cancer&#xD;
&#xD;
          -  Bilateral breast cancer&#xD;
&#xD;
          -  Undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph&#xD;
             nodes&#xD;
&#xD;
          -  Axillary lymph node dissection prior to initiation of neoadjuvant therapy&#xD;
&#xD;
          -  History of other malignancy within 5 years prior to screening, with the exception of&#xD;
             those with a negligible risk of metastasis or death&#xD;
&#xD;
          -  Cardiopulmonary dysfunction&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
          -  Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells&#xD;
&#xD;
          -  Known allergy or hypersensitivity to the components of the formulations of&#xD;
             atezolizumab, nab-paclitaxel, cyclophosphamide, or doxorubicin, filgrastim or&#xD;
             pegfilgrastim&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency diseases except history&#xD;
             of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus, and&#xD;
             dermatologic manifestations of eczema, psoriasis, lichen simplex chronicus, or&#xD;
             vitiligo (e.g., participants with psoriatic arthritis are excluded)&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation&#xD;
             field (fibrosis) is permitted&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) test at screening&#xD;
&#xD;
          -  Active hepatitis B and hepatitis C virus infection&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Severe infections within 4 weeks prior to initiation of study treatment, including but&#xD;
             not limited to hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia&#xD;
&#xD;
          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation&#xD;
             of study treatment, except prophylactic antibiotics&#xD;
&#xD;
          -  Major surgical procedure within 4 weeks prior to initiation of study treatment or&#xD;
             anticipation of need for a major surgical procedure during the course of the study&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Administration of a live attenuated vaccine within 4 weeks prior to initiation of&#xD;
             study treatment or anticipation of need for such a vaccine during the study&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the participant at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune&#xD;
             checkpoint-blockade therapies, including anti-cluster of differentiation 40&#xD;
             (anti-CD40), anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4),&#xD;
             anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the&#xD;
             drug, whichever is longer, prior to initiation of study treatment&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to&#xD;
             initiation of study treatment or anticipation of need for systemic immunosuppressive&#xD;
             medications during the study&#xD;
&#xD;
          -  History of cerebrovascular accident within 12 months prior to randomization&#xD;
&#xD;
          -  Pregnant or lactating, or intending to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital</name>
      <address>
        <city>Carrollton</city>
        <state>Georgia</state>
        <zip>30117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Division</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital; Valley Medical Group</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit</name>
      <address>
        <city>Bull Creek</city>
        <state>Western Australia</state>
        <zip>6149</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Augustinus Wilrijk</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Salvador</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Araujo Jorge; Departamento de Ginecologia E Mama</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74605-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CETUS Hospital Dia Oncologia</name>
      <address>
        <city>Uberaba</city>
        <state>MG</state>
        <zip>38082-049</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iop Instituto de Oncologia Do Parana</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80530-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinicas Oncologicas Integradas - COI</name>
      <address>
        <city>Rio De Janeiro</city>
        <state>RJ</state>
        <zip>22290-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas - PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Oncologicas - CEPON</name>
      <address>
        <city>Florianopolis</city>
        <state>SC</state>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01317-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sacre-Coeur Research Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hochwaldkrankenhaus</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare)</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters</name>
      <address>
        <city>Berlin</city>
        <zip>13581</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luisenkrankenhaus GmbH &amp; Co. KG., Brustzentrum</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40235</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken Gelsenkirchen GmbH; Brustzentrum</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem</name>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakovere Henriettenstift, Frauenklinik</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres. Andreas Köhler und Roswitha Fuchs</name>
      <address>
        <city>Langen</city>
        <zip>63225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth-Krankenhaus, Senologie/Brustzentrum</name>
      <address>
        <city>Leipzig</city>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik &amp; Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum am Klinikum Oldenburg GmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ULSS 8 Berica; Oncologia Medica - Ospedlae di Vicenza</name>
      <address>
        <city>Vicenza</city>
        <state>Veneto</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Aichi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Ehime</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital; Breast Surgery</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Kanagawa</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital; Breast Surgery</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Internat. Hospital, Breast Surgical Oncology</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Inst. Hosp. of JFCR; Breast Oncology Center</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnośląskie Centrum Onkologii; Oddział Onkologii Klinicznej i Chemioterapii</name>
      <address>
        <city>Wrocław</city>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VETERANS GENERAL HOSPITAL; Department of General Surgery</name>
      <address>
        <city>Taipei</city>
        <zip>00112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital; Dept of Surgery</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation Linkou Branch</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts &amp; London School of Med; Medical Oncology</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <results_first_submitted>March 29, 2021</results_first_submitted>
  <results_first_submitted_qc>May 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2021</results_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03197935/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03197935/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo and Chemotherapy</title>
          <description>Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will continue to be followed after surgery.</description>
        </group>
        <group group_id="P2">
          <title>Atezolizumab and Chemotherapy</title>
          <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death due to any cause</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On-Going in Study</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive any study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo and Chemotherapy</title>
          <description>Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will continue to be followed after surgery.</description>
        </group>
        <group group_id="B2">
          <title>Atezolizumab and Chemotherapy</title>
          <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="13.2"/>
                    <measurement group_id="B2" value="50.1" spread="11.6"/>
                    <measurement group_id="B3" value="50.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="333"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population</title>
        <description>Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population. pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR.</description>
        <time_frame>After neoadjuvant study treatment and surgery, up to data cut-off on 03 ApriI 2020</time_frame>
        <population>ITT population (full population) is defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Chemotherapy</title>
            <description>Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will continue to be followed after surgery.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab and Chemotherapy</title>
            <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population</title>
          <description>Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population. pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR.</description>
          <population>ITT population (full population) is defined as all randomized participants.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0044</p_value>
            <p_value_desc>(one-sided)</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in pCR</param_type>
            <param_value>16.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.91</ci_lower_limit>
            <ci_upper_limit>27.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System</title>
        <description>Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in the subpopulation with programmed death-ligand1 (PD-L1)-positive tumor status(tumor-infiltrating immune cell [IC] IC1/2/3) . pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR.</description>
        <time_frame>After neoadjuvant study treatment and surgery, up to data cut-off on 03 ApriI 2020</time_frame>
        <population>PD-L1-positive subpopulation is defined as participants in the ITT population whose PD-L1 status is IC1/2/3 at the time of randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Chemotherapy</title>
            <description>Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will continue to be followed after surgery.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab and Chemotherapy</title>
            <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System</title>
          <description>Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in the subpopulation with programmed death-ligand1 (PD-L1)-positive tumor status(tumor-infiltrating immune cell [IC] IC1/2/3) . pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR.</description>
          <population>PD-L1-positive subpopulation is defined as participants in the ITT population whose PD-L1 status is IC1/2/3 at the time of randomization.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0206</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in pCR</param_type>
            <param_value>19.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.17</ci_lower_limit>
            <ci_upper_limit>34.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-Free Survival (EFS) in All Participants</title>
        <description>Event-free survival (EFS) defined as the time from randomization until documented disease recurrence, progression, or death from any cause in all participants. EFS events covered under &quot;disease recurrence&quot; will include local, regional, or distant recurrence and contralateral breast cancer. Ipsilateral or contralateral in situ disease and second primary non-breast cancers will not be counted as EFS events.</description>
        <time_frame>Baseline up to approximately 63 months</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-Free Survival (EFS) in Subpopulation With PD-L1-Postive Tumor Status</title>
        <description>Event-free survival (EFS) defined as the time from randomization until documented disease recurrence, progression, or death from any cause in the subpopulation with PD-L1-positive tumor status. EFS events covered under &quot;disease recurrence&quot; will include local, regional, or distant recurrence and contralateral breast cancer. Ipsilateral or contralateral in situ disease and second primary non-breast cancers will not be counted as EFS events.</description>
        <time_frame>Baseline up to approximately 63 months</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-Free Survival (DFS) in All Participants Who Undergo Surgery</title>
        <description>Disease-free survival (DFS) defined as the time from surgery until documented disease recurrence or death from any cause in all patients (ITT population) who undergo surgery.</description>
        <time_frame>Baseline up to approximately 63 months</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-Free Survival (DFS) in Subpopulation of Participants With PD-L1-Positive Tumor Status Who Undergo Surgery</title>
        <description>Disease-free survival (DFS) defined as the time from surgery until documented disease recurrence or death from any cause in the subpopulation of participants with PD-L1-positive tumor status who undergo surgery.</description>
        <time_frame>Baseline up to approximately 63 months</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in All Participants</title>
        <description>Overall survival (OS) defined as the time from randomization to the date of death from any cause in all participants.</description>
        <time_frame>Baseline up to approximately 63 months</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in Subpopulation With PD-L1-Positive Tumor Status</title>
        <description>Overall survival (OS) defined as the time from randomization to the date of death from any cause in the subpopulation with PD-L1-positive tumor status.</description>
        <time_frame>Baseline up to approximately 63 months</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Scores for Function (Role/Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30</title>
        <description>Mean score in function (role, physical) and global health status(GHS)/ health-related quality of life (HRQoL) by cycle and between treatment arms as assessed by the functional and HRQoL scales of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core30(QLQ C30). The EORTC QLQ-C30 includes five functional scales; a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms).</description>
        <time_frame>Baseline (Cycle 1 Day 1), on Day 1 of every cycle (C) thereafter (C=28 days from C1 to 5, and 21 days from C6 to 16), at Study Drug Completion/Early Discontinuation, Survival Follow-Up Months 3, 6, 9, 12, 18 and 24 (up to approximately 63 months)</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Scores for Function (Role, Physical) and GHS/HRQoL by Cycle and Between Treatment Arms as Assessed by the EORTC QLQ-C30</title>
        <description>Mean change from baseline score in function (role, physical) andglobal health status(GHS)/ health-related quality of life (HRQoL) by cycle and between treatment arms as assessed by the functional and HRQoL scales of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core30(QLQ C30). Note: Cycle=C; Day=D.</description>
        <time_frame>Baseline (Cycle 1 Day 1), and on Day 1 of every cycle (C) thereafter (C length=28 days from C1 to 5, and 21 days from C6 to 16), at Study Drug Completion/Early Termination, Survival Follow-Up Months 12, 18, and 24 (up to approximately 63 months)</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>Percentage of participants with adverse events.</description>
        <time_frame>Baseline up to approximately 63 months</time_frame>
        <posting_date>10/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Serum Atezolizumab Concentration (Cmin)</title>
        <description>Minimum observed serum atezolizumab concentration.</description>
        <time_frame>Pre-dose on Day 1 of Cycles 2, 3, 4, 6, 8, 12, and 16 (cycle length = 28 days from Cycles 1 to 5, and 21 days from Cycles 6 to 16)</time_frame>
        <population>The pharmacokinetic-evaluable population is defined as all participants who received any dose of atezolizumab and who have evaluable pharmacokinetic (PK) samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab and Chemotherapy</title>
            <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Serum Atezolizumab Concentration (Cmin)</title>
          <description>Minimum observed serum atezolizumab concentration.</description>
          <population>The pharmacokinetic-evaluable population is defined as all participants who received any dose of atezolizumab and who have evaluable pharmacokinetic (PK) samples.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" spread="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189" spread="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207" spread="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" spread="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" spread="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303" spread="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Atezolizumab Concentration (Cmax)</title>
        <description>Maximum observed atezolizumab concentration (Cmax).</description>
        <time_frame>Day 1 of Cycle 1 post dose (cycle length = 28 days)</time_frame>
        <population>The pharmacokinetic-evaluable population is defined as all participants who received any dose of atezolizumab and who have evaluable pharmacokinetic (PK) samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab and Chemotherapy</title>
            <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Atezolizumab Concentration (Cmax)</title>
          <description>Maximum observed atezolizumab concentration (Cmax).</description>
          <population>The pharmacokinetic-evaluable population is defined as all participants who received any dose of atezolizumab and who have evaluable pharmacokinetic (PK) samples.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334" spread="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab</title>
        <description>Percentage of participants with anti-drug antibodies (ADAs) to atezolizumab.</description>
        <time_frame>Baseline up to approximately 20 months</time_frame>
        <population>The anti-drug antibodies (ADA)-evaluable population is defined as all participants treated with atezolizumab who have at least one post-baseline ADA result.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab and Chemotherapy</title>
            <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab</title>
          <description>Percentage of participants with anti-drug antibodies (ADAs) to atezolizumab.</description>
          <population>The anti-drug antibodies (ADA)-evaluable population is defined as all participants treated with atezolizumab who have at least one post-baseline ADA result.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline evaluable participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-baseline evaluable participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first study drug to the data cutoff date 3 April 2020 (up to approximately 32 months)</time_frame>
      <desc>Safety evaluable population is defined as all participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atezolizumab + Nab-paclitaxel + AC</title>
          <description>Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Nab-paclitaxel + AC</title>
          <description>Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOPITUITARISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACILLUS BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CANDIDA INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MASTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PERIORBITAL CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECII PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS CHEMICAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>GUILLAIN-BARRE SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL INFARCT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DERMATOMYOSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="87" subjects_affected="64" subjects_at_risk="164"/>
                <counts group_id="E2" events="78" subjects_affected="63" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="42" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E2" events="28" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="137" subjects_affected="64" subjects_at_risk="164"/>
                <counts group_id="E2" events="122" subjects_affected="59" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="164"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="73" subjects_affected="51" subjects_at_risk="164"/>
                <counts group_id="E2" events="63" subjects_affected="54" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="106" subjects_affected="73" subjects_at_risk="164"/>
                <counts group_id="E2" events="117" subjects_affected="74" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="164"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="214" subjects_affected="107" subjects_at_risk="164"/>
                <counts group_id="E2" events="189" subjects_affected="110" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="48" subjects_affected="40" subjects_at_risk="164"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="100" subjects_affected="62" subjects_at_risk="164"/>
                <counts group_id="E2" events="70" subjects_affected="51" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="66" subjects_affected="42" subjects_at_risk="164"/>
                <counts group_id="E2" events="40" subjects_affected="36" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="91" subjects_affected="62" subjects_at_risk="164"/>
                <counts group_id="E2" events="84" subjects_affected="64" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="34" subjects_affected="15" subjects_at_risk="164"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="164"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="164"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="164"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="55" subjects_affected="36" subjects_at_risk="164"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="164"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="164"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="164"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="164"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RADIATION SKIN INJURY</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="61" subjects_affected="38" subjects_at_risk="164"/>
                <counts group_id="E2" events="54" subjects_affected="35" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="59" subjects_affected="36" subjects_at_risk="164"/>
                <counts group_id="E2" events="43" subjects_affected="27" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BLOOD LACTATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="61" subjects_affected="29" subjects_at_risk="164"/>
                <counts group_id="E2" events="67" subjects_affected="30" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="164"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="33" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E2" events="35" subjects_affected="15" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="164"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="61" subjects_affected="38" subjects_at_risk="164"/>
                <counts group_id="E2" events="59" subjects_affected="39" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="84" subjects_affected="51" subjects_at_risk="164"/>
                <counts group_id="E2" events="49" subjects_affected="40" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="33" subjects_affected="27" subjects_at_risk="164"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="31" subjects_affected="18" subjects_at_risk="164"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="76" subjects_affected="50" subjects_at_risk="164"/>
                <counts group_id="E2" events="45" subjects_affected="35" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="47" subjects_affected="39" subjects_at_risk="164"/>
                <counts group_id="E2" events="42" subjects_affected="34" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="64" subjects_affected="57" subjects_at_risk="164"/>
                <counts group_id="E2" events="46" subjects_affected="43" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TASTE DISORDER</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="58" subjects_affected="46" subjects_at_risk="164"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="51" subjects_affected="40" subjects_at_risk="164"/>
                <counts group_id="E2" events="39" subjects_affected="32" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="164"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="164"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="126" subjects_affected="124" subjects_at_risk="164"/>
                <counts group_id="E2" events="132" subjects_affected="129" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="164"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NAIL DISCOLOURATION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="164"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="164"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="45" subjects_affected="33" subjects_at_risk="164"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="65" subjects_affected="51" subjects_at_risk="164"/>
                <counts group_id="E2" events="53" subjects_affected="42" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="164"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="26" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

